CTOs on the Move


 
Inari embraces diversity in every aspect of our business to drive innovation and help build a new food system. Our technology matches the complexity of nature to transform seed using predictive design and multiplex gene editing – unlocking the full potential through our SEEDesign™ platform. The result is step-change products that lead to more productive acres and a more sustainable future for the food system.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.inari.com
  • One Kendall Square Building 600/700 Suite 7-501
    Cambridge, MA USA 02139
  • Phone: 774.489.5343

Executives

Name Title Contact Details
Rania Khalaf
Chief Information and Data Officer Profile

Funding

Inari raised $40M on 08/09/2018
Inari raised $89M on 08/01/2019
Inari raised $45M on 04/22/2020
Inari raised $208M on 05/12/2021

Similar Companies

ABclonal

Based in Massachusetts, ABclonal is a dynamic and growing provider of biology research reagents and services. With scientists from world-class universities, we thrive to improve the quality of life science research by providing high-quality antibodies, proteins, ELISA kits, NGS Prep Kits and molecular enzymes.

Seed IP

Seed IP is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Phycotransgenics

Phycotransgenics is a Bloomington, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ambagon Therapeutics

Ambagon’s approach selectively augments the endogenous tumor suppression activity of 14-3-3 proteins bound to transcription factors and oncoproteins that have proven challenging to modulate with conventional approaches. Ambagon’s platform approach will...

Seres Therapeutics

Seres Therapeutics is a clinical stage biotherapeutic company focused on discovering and developing Ecobiotic™ therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. Founded by Flagship VentureLabs, Seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. Current candidates span infectious, metabolic, and inflammatory diseases.